LA LABLA LAB
Research Reference Document
Compound Guide
DSIP — Delta Sleep-Inducing Peptide
9-AA neuropeptide · discovered 1977 · not approved by SAHPRA, FDA or EMA · SubQ
Quick Start
What It Is
DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 by Schoenenberger and Monnier in Basel, from the cerebral venous blood of rabbits kept in induced slow-wave (delta) sleep. It is named for the delta-wave sleep it was found alongside. Nearly fifty years later its receptor and its natural role in the body are still not established.
Research Dosing
100–300 mcg SubQ, once daily, 30–60 minutes before bed. Community protocols start at 100 mcg and rarely go above 300 mcg; higher doses have not been shown to work better. Human studies from the 1980s mostly used an intravenous dose of about 25 nmol/kg, which is not the same as a SubQ research dose.
Cycle Structure
2–4 weeks on, then 1–2 weeks off, or only on nights when it is needed. There is no published human data on long-term or continuous use.
Regulatory Status
Not approved by SAHPRA, the FDA or the EMA for any use. Not on the WADA prohibited list by name. Sold by LA LAB for research purposes only, 18+.
Dosing Protocol
RouteDoseTimingDurationNotes
SubQ100–300 mcgOnce daily, 30–60 min before bed2–4 weeks on, 1–2 weeks offStart at 100 mcg (6 units); increase slowly only if needed
As needed100–200 mcgOn nights requiredIntermittentCommon alternative to daily use
Supplies & Reconstitution (SubQ)

Reconstitution Math — 5 mg Vial (3 mL BAC)

Target DoseUnits (U-100) = Pen ClicksDoses / Vial
100 mcg6 units50
150 mcg9 units33.3
200 mcg12 units25
250 mcg15 units20
300 mcg18 units16.7
500 mcg30 units10
Reconstitute the 5 mg vial with 3.0 mL bacteriostatic water → 1.67 mg/mL (1,667 mcg/mL). 1 unit = 1 pen click = 16.7 mcg. U-100 syringe = 100 units per mL. Swirl gently — do not shake. Refrigerate 2–8°C.

Reconstitution Steps

01
Warm the vial
Allow the powder vial to reach room temperature before mixing.
02
Swab and draw
Alcohol swab both vial tops and let them dry. Draw 3.0 mL bacteriostatic water.
03
Inject along the wall
Run the water slowly down the inside glass wall. Do not jet it onto the powder.
04
Swirl gently
Swirl until clear and fully dissolved. Do not shake.
05
Refrigerate
Store at 2–8°C, protected from light. Use within 30 days. Do not freeze after mixing.
Mechanism of Action
ℹ️
No confirmed receptor
No specific DSIP receptor has been identified. The mechanisms below are proposals from animal and cell research, and some findings have not been reproduced. A 2006 review in the Journal of Neurochemistry called DSIP “a still unresolved riddle”.
Sleep architecture
Early animal work linked DSIP to more slow-wave (delta) sleep. Later studies were inconsistent: some found an effect on sleep patterns, others found none.
Stress-axis signalling
Studied for effects on the hypothalamic–pituitary–adrenal axis, including reduced ACTH and corticosterone responses to stress in animal models.
Neurotransmitter interaction
Proposed interactions with GABA, glutamate (NMDA) and serotonin signalling in the brain. None is established as the main mechanism.
Antioxidant / adaptive
Animal studies report antioxidant and stress-protective effects, sometimes described as “adaptogenic”. This has not been tested in human trials.
Research Status
⚠️
Old, small and inconsistent data
Most human DSIP research is from the late 1970s and 1980s, in small groups, and the results were mixed. There is no modern controlled trial programme. Treat every effect below as unconfirmed.
Study TypeFindingLimitation
Animal studies (1977 onwards)Increased delta-wave sleep in some modelsNot consistently reproduced across species and labs
Small human studies, chronic insomnia (1980s)Some improvement in sleep efficiency reported in a few patientsSmall groups; mixed results; IV dosing
Withdrawal studies (1984)Reduced symptoms reported in alcohol and opiate withdrawalOpen studies; not confirmed by later trials
Review (2006)Physiological role still unclearReceptor and mechanism unresolved
Storage
StateTemperatureDurationNotes
Powder (unmixed)−20°C freezer, or 2–8°C short termUp to 24 months frozenProtect from light and moisture
Mixed (liquid)2–8°C (refrigerator)Up to 30 daysDo not freeze after mixing
⚠️
Disclaimer
This document is an educational research reference only. DSIP is not approved by SAHPRA, the FDA or the EMA. By purchasing from LA LAB you confirm you are 18+ and that products are for research purposes only.
Side Effects & What People Report

There is no modern safety trial for DSIP, so there are no reliable incidence figures. The reports below come from the small older studies and from the research community.

ReportedDetail
Nothing at allThe most common report. Many people notice no difference in their sleep.
Morning grogginessReported more at higher doses (300 mcg and above). Lower the dose if it happens.
Vivid dreamsOccasionally reported.
HeadacheOccasionally reported, usually mild.
Injection-site rednessAs with any SubQ injection.
Who Should Avoid DSIP
SituationWhy
Pregnancy or breastfeedingAvoid. There is no safety data.
Under 18No data.
Taking sleeping tablets, sedatives or psychiatric medicationDSIP may act on GABA and serotonin signalling. Speak to a prescriber before combining it with anything.
Possible sleep apnoea or a sleep disorderSnoring with pauses in breathing, or long-term insomnia, needs a proper medical assessment first.
Driving or operating machineryWait until you know how it affects you the next morning.
Frequently Asked Questions
Is it a sleeping pill?
No. It is not a sedative, and it does not knock you out. Research looked at sleep quality and depth, and results were mixed.
When should I inject it?
30–60 minutes before bed is the usual research timing.
How quickly will I notice anything?
Some people report deeper sleep within a few nights; many notice nothing. There is no reliable data to predict which.
Is it addictive?
No dependence has been reported, but long-term use has never been studied.
Can it replace my sleep medication?
No. Do not stop a prescribed treatment for a research peptide.
Sources & Research
Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA 1977;74:1282–6.
Schneider-Helmert D et al. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol 1981;19:341–5.
Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol 1984;23:364–71.
Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem 2006;97:303–9.
Regulatory status — not approved by SAHPRA, the FDA or the EMA.
Educational reference only
This document is a research reference, not medical advice and not a treatment plan. DSIP has no modern human trial programme and its mechanism is unresolved. Dose decisions belong to you and your prescriber. Independent certificates of analysis for LA LAB batches are published under Research → Lab Results, with the Janoshik task number and verification key so you can check them yourself.